Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Dr. Shireesh Ambhaikar, Chief Executive Officer and a Key Managerial Personnel of the company, has resigned from the position due to his personal reasons and requested, inter alia, for acceptance of his resignation and relieving him by September 30, 2022 and which has been accepted by the Board in its meeting held today i.e. September 27, 2022.
However, Dr. Shireesh Ambhaikar has agreed to extend his services on a retainership basis for a period of 2 (two) years effective October 1, 2022 where he will be designated as Technical Head for certain projects of Supriya Lifescience Limited to ensure their timely execution, knowledge transfer and smooth transition to his successor, who will be joining the company on October 3, 2022.
The Board has in its meeting held today i.e. September 27, 2022 approved the appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer and Key Managerial Personnel of the Company, who will be joining on October 3, 2022 to take Supriya on the next phase of its growth journey.
The Board would like to take this opportunity to express its gratitude to Dr. Shireesh Ambhaikar for his contribution to the Company during his tenure of office and look forward for his continued support and guidance in his new role.
Source: BSE filing
Subscribe To Our Free Newsletter |